Catalyst Pharmaceuticals Ownership | Who Owns Catalyst Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Catalyst Pharmaceuticals Ownership Summary


Catalyst Pharmaceuticals is owned by 84.46% institutional investors, 6.32% insiders, and 9.21% retail investors. Blackrock is the largest institutional shareholder, holding 16.01% of CPRX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.57% of its assets in Catalyst Pharmaceuticals shares.

CPRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCatalyst Pharmaceuticals84.46%6.32%9.21%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock18.69M16.01%$289.58M
Blackrock funding, inc. /de18.22M14.91%$358.86M
Vanguard group8.71M7.13%$171.66M
State street6.41M5.24%$126.19M
Deerfield management company, l.p. (series c)4.97M4.07%$98.00M
Renaissance3.54M2.90%$69.83M
Fundsmith llp3.36M2.75%$66.27M
Geode capital management2.89M2.37%$56.95M
American century companies2.53M2.07%$49.81M
Dimensional fund advisors lp2.46M2.01%$48.42M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tanaka capital management114.42K4.06%$2.25M
Gables capital management435.42K3.68%$8.58M
Jw asset management388.39K3.67%$7.65M
Knott david m jr189.00K1.50%$3.72M
Deerfield management company, l.p. (series c)4.97M1.50%$98.00M
Mesirow institutional investment management742.29K1.19%$15.49M
Qsv equity investors53.49K1.08%$1.05M
Bridge city capital182.30K0.96%$3.59M
Globeflex capital l p290.68K0.88%$5.73M
Pvg asset management11.79K0.72%$182.56K

Top Buyers

HolderShares% AssetsChange
Deerfield management company, l.p. (series c)4.97M1.50%2.10M
Blackrock18.69M0.01%962.28K
State street6.41M0.00%927.00K
American century companies2.53M0.03%770.20K
Fundsmith llp3.36M0.33%654.72K

Top Sellers

HolderShares% AssetsChange
Goldman sachs group1.01M0.00%-1.40M
Morgan stanley1.84M0.00%-1.34M
Blackrock funding, inc. /de18.22M0.01%-684.38K
Point72 asset management---618.30K
Nuveen542.23K0.00%-444.04K

New Positions

HolderShares% AssetsChangeValue
Eversept partners, lp350.81K0.48%350.81K$6.91M
Brandywine global investment management310.99K0.04%310.99K$6.13M
Alyeska investment group273.29K0.02%273.29K$5.38M
Wedge capital management l l p/nc145.17K0.05%145.17K$2.86M
Tanaka capital management114.42K4.06%114.42K$2.25M

Sold Out

HolderChange
Global financial private client-1.00
Coppell advisory solutions-8.00
Mendota financial group-12.00
Strengthening families & communities-15.00
Richards, merrill & peterson-15.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025351-3.57%103,180,9191.77%841.23%169-19.52%1295.74%
Jun 30, 2025354-3.54%101,094,7563.01%821.27%2043.55%118-2.48%
Mar 31, 20253616.80%97,419,101-0.16%801.19%193-4.46%11933.71%
Dec 31, 20243294.44%99,023,9753.92%831.30%19521.88%87-17.14%
Sep 30, 202431314.65%95,228,606-1.82%801.16%15925.20%10418.18%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF6.82M5.57%-
Vanguard Total Stock Mkt Idx Inv3.63M2.97%-77.47K
Vanguard US Total Market Shares ETF3.55M2.91%3.78K
iShares Russell 2000 ETF2.78M2.27%-
Smithson Investment Trust Ord2.71M2.21%-
First Trust NYSE Arca Biotech ETF1.89M1.59%-
Avantis US Small Cap Value ETF1.80M1.47%14.54K
Vanguard Institutional Extnd Mkt Idx Tr1.23M1.01%-534.49K
SPDR® S&P Biotech ETF1.17M0.95%2.60K
Fidelity Small Cap Index1.16M0.95%15.51K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 26, 2025Del Carmen Jeffrey Chief Commercial OfficerSell$256.24K
Nov 12, 2025Elsbernd Brian Chief Compliance/Legal OfficerBuy$908.00K
Sep 08, 2025Elsbernd Brian Chief Compliance/Legal OfficerSell$609.00K
Sep 04, 2025Elsbernd Brian Chief Compliance/Legal OfficerSell$585.60K
Sep 03, 2025Elsbernd Brian Chief Compliance/Legal OfficerSell$401.60K

Insider Transactions Trends


DateBuySell
2025 Q4-2
2025 Q3-6
2025 Q2-7
2025 Q1-5
2024 Q4-14

CPRX Ownership FAQ


Who Owns Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals shareholders are primarily institutional investors at 84.46%, followed by 6.32% insiders and 9.22% retail investors. The average institutional ownership in Catalyst Pharmaceuticals's industry, Biotech Stocks , is 45.22%, which Catalyst Pharmaceuticals exceeds.

Who owns the most shares of Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals’s largest shareholders are Blackrock (18.69M shares, 16.01%), Blackrock funding, inc. /de (18.22M shares, 14.91%), and Vanguard group (8.71M shares, 7.13%). Together, they hold 38.05% of Catalyst Pharmaceuticals’s total shares outstanding.

Does Blackrock own Catalyst Pharmaceuticals?

Yes, BlackRock owns 16.01% of Catalyst Pharmaceuticals, totaling 18.69M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 289.58M$. In the last quarter, BlackRock increased its holdings by 962.28K shares, a 5.43% change.

Who is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Tanaka capital management is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 4.06% of its assets in 114.42K Catalyst Pharmaceuticals shares, valued at 2.25M$.

Who is the top mutual fund holder of Catalyst Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Catalyst Pharmaceuticals shares, with 5.57% of its total shares outstanding invested in 6.82M Catalyst Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools